Ginkgo Bioworks Surges 18.9%, Can Further Upside Be Expected?
ByAinvest
Tuesday, Jul 1, 2025 8:05 am ET1min read
DNA--
The consensus EPS estimate has been revised 12.1% lower over the last 30 days, indicating a shift in analyst sentiment. Despite this, DNA carries a Zacks Rank #2 (Buy) and is part of the Medical - Biomedical and Genetics industry, which ranks in the top 34% of all industries [2].
Institutional investors have also shown interest in Ginkgo Bioworks. During the fourth quarter, SBI Securities Co. Ltd. bought a new stake worth approximately $29,000, while US Bancorp DE grew its stake by 43.5% in the first quarter. KLP Kapitalforvaltning AS and CWM LLC also increased their stakes in the company [1].
Ginkgo Bioworks, headquartered in the United States, develops a platform for cell programming. Its platform is used to program cells to enable biological production of products such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves a variety of industries, including pharmaceuticals, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense [1].
References:
[1] https://www.marketbeat.com/instant-alerts/ginkgo-bioworks-nysedna-shares-up-134-still-a-buy-2025-06-30/
[2] https://www.nasdaq.com/articles/ginkgo-bioworks-holdings-inc-dna-stock-moves-141-what-you-should-know
Ginkgo Bioworks Holdings (DNA) shares surged 18.9% to $11.25, driven by positive investor expectations for its proprietary cell programming platforms, Foundry and Codebase. The company is expected to post a quarterly loss of $1.44 per share and revenues of $43 million. The consensus EPS estimate has been revised 12.1% lower over the last 30 days. DNA carries a Zacks Rank #2 (Buy) and is part of the Medical - Biomedical and Genetics industry.
Ginkgo Bioworks Holdings, Inc. (DNA) experienced a significant 18.9% increase in its stock price, reaching $11.25 on Monday, June 19, 2025. The surge was driven by positive investor expectations for the company's proprietary cell programming platforms, Foundry and Codebase. Analysts anticipate that Ginkgo Bioworks will report a quarterly loss of $1.44 per share and revenues of $43 million [1].The consensus EPS estimate has been revised 12.1% lower over the last 30 days, indicating a shift in analyst sentiment. Despite this, DNA carries a Zacks Rank #2 (Buy) and is part of the Medical - Biomedical and Genetics industry, which ranks in the top 34% of all industries [2].
Institutional investors have also shown interest in Ginkgo Bioworks. During the fourth quarter, SBI Securities Co. Ltd. bought a new stake worth approximately $29,000, while US Bancorp DE grew its stake by 43.5% in the first quarter. KLP Kapitalforvaltning AS and CWM LLC also increased their stakes in the company [1].
Ginkgo Bioworks, headquartered in the United States, develops a platform for cell programming. Its platform is used to program cells to enable biological production of products such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves a variety of industries, including pharmaceuticals, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense [1].
References:
[1] https://www.marketbeat.com/instant-alerts/ginkgo-bioworks-nysedna-shares-up-134-still-a-buy-2025-06-30/
[2] https://www.nasdaq.com/articles/ginkgo-bioworks-holdings-inc-dna-stock-moves-141-what-you-should-know
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet